Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1936 to 1950 of 7682 results

  1. Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

  2. Masitinib with riluzole for treating amyotrophic lateral sclerosis ID6257

    In development [GID-TA11071] Expected publication date: TBC

  3. Kidney Cancer

    In development [GID-QS10186] Expected publication date: TBC

  4. IgPro20 for treating dermatomyositis TS ID 12014

      Status ...

  5. High-dose aflibercept for treating wet age-related macular degeneration TS ID 10590

      Status ...

  6. Aflibercept for untreated diabetic macular oedema TS ID 10621

      Status ...

  7. Lymphatico-venous anastomosis for chronic lymphoedema

    Register an interest in this interventional procedure   ...

  8. Sacituzumab govitecan for untreated PD-L1-negative triple-negative advanced breast cancer ID6433

    Awaiting development [GID-TA11489] Expected publication date: TBC

  9. Pembrolizumab for adjuvant treatment of hepatocellular carcinoma [ID3994]

    Awaiting development [GID-TA10895] Expected publication date: TBC

  10. Somapacitan for treating growth hormone deficiency in children [ID6178]

    In development [GID-TA11153] Expected publication date: TBC

  11. Liposomal bupivacaine for treating postoperative pain [ID3799]

    The topic was stopped after scoping, this means the topic will not proceed to a Technology Appraisal   ...

  12. Ensitrelvir for treating COVID-19 [ID6231]

    Awaiting development [GID-TA11224] Expected publication date: TBC

  13. RenalGuard Therapy for reduction in the incidence of Contrast-Associated AKI (CA-AKI) in at-risk patients

    Register an interest in this interventional procedure   ...

  14. Ruxolitinib for treating acute graft-versus-host disease after allogeneic stem cell transplant in people 28 days to 17 years [ID6410]

    Awaiting development [GID-TA11494] Expected publication date: TBC